Literature DB >> 6304695

Complete differentiation between enkephalinase and angiotensin-converting enzyme inhibition by retro-thiorphan.

B P Roques, E Lucas-Soroca, P Chaillet, J Costentin, M C Fournié-Zaluski.   

Abstract

Thiorphan, N-[(R,S)-3-mercapto-2-benzylpropanoyl]glycine is a highly potent inhibitor (Ki = 3.5 nM) of "enkephalinase," a metalloendopeptidase cleaving the Gly-Phe bond (positions 3 and 4) of enkephalins in brain tissue. In accordance with this property, thiorphan displays antinociceptive activity after systemic administration. However, thiorphan also inhibits to a lesser extent (Ki = 140 nM) the widely distributed angiotensin-converting enzyme, a carboxydipeptidase implicated in blood pressure regulation. Therefore, in view of an eventual clinical use of enkephalinase inhibitors, it was very important to develop fully specific compounds. Such derivatives were obtained taking into account that N-methylation of the ultimate amide bond of dipeptides strongly decreases enkephalinase affinity without affecting angiotension-converting enzyme recognition, whereas retro-inversion of the amide bond leads to the inverse effect. Thus, the retro-inverso dipeptide (R)-H2N-CH(CH2 phi)-NHCO-CH2-CO2H exhibits an inhibitory potency on enkephalinase (IC50 approximately equal to 12 muM) close to that of the natural dipeptide L-Phe-Gly (IC50 approximately equal to 3 muM). This result shows the topological analogy between the crucial components involved in enkephalinase recognition both in active dipeptides and structurally related retro-inverso isomers. Taking into account these observations, retro-thiorphan, (R,S)-HS-CH2-CH-(CH2 phi)-NHCO-CH2-COOH, was prepared. As compared to thiorphan, the retro isomer is 50% as potent (Ki = 6 nM) on enkephalinase but displays a drastic loss of potency on angiotension-converting enzyme (IC50 greater than 10,000 nM). This specificity was interpreted as a consequence of differences in the stereochemical constraints involving enzyme-inhibitor hydrogen bonding. This hypothesis is supported by reported crystallographic studies on related enzymes such as thermolysin and carboxypeptidase A. As expected, retro-thiorphan exhibits about the same analgesic potency as thiorphan on the hot plate and writhing tests in mice. Therefore, the topological concept of retro-inverso isomers could be extended to other enkephalinase inhibitors, allowing the design of potent and highly selective compounds occurring as new classes of analgesic and psychoactive agents.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6304695      PMCID: PMC394003          DOI: 10.1073/pnas.80.11.3178

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

1.  High-affinity enkephalin-degrading peptidase in brain is increased after morphine.

Authors:  B Malfroy; J P Swerts; A Guyon; B P Roques; J C Schwartz
Journal:  Nature       Date:  1978-11-30       Impact factor: 49.962

2.  Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids.

Authors:  D W Cushman; H S Cheung; E F Sabo; M A Ondetti
Journal:  Biochemistry       Date:  1977-12-13       Impact factor: 3.162

3.  Mode of deactivation of the enkephalins by rat and human plasma and rat brain homogenates.

Authors:  J M Hambrook; B A Morgan; M J Rance; C F Smith
Journal:  Nature       Date:  1976-08-26       Impact factor: 49.962

4.  A crystallographic study of the complex of phosphoramidon with thermolysin. A model for the presumed catalytic transition state and for the binding of extended substances.

Authors:  L H Weaver; W R Kester; B W Matthews
Journal:  J Mol Biol       Date:  1977-07       Impact factor: 5.469

5.  Design of potent and specific inhibitors of carboxypeptidases A and B.

Authors:  M A Ondetti; M E Condon; J Reid; E F Sabo; H S Cheung; D W Cushman
Journal:  Biochemistry       Date:  1979-04-17       Impact factor: 3.162

6.  Hydrolysis of enkephalin by cultured human endothelial cells and by purified peptidyl dipeptidase.

Authors:  E G Erdös; A R Johnson; N T Boyden
Journal:  Biochem Pharmacol       Date:  1978-03-01       Impact factor: 5.858

7.  Identification of two related pentapeptides from the brain with potent opiate agonist activity.

Authors:  J Hughes; T W Smith; H W Kosterlitz; L A Fothergill; B A Morgan; H R Morris
Journal:  Nature       Date:  1975-12-18       Impact factor: 49.962

8.  Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents.

Authors:  M A Ondetti; B Rubin; D W Cushman
Journal:  Science       Date:  1977-04-22       Impact factor: 47.728

9.  The purification and specificity of a neutral endopeptidase from rabbit kidney brush border.

Authors:  M A Kerr; A J Kenny
Journal:  Biochem J       Date:  1974-03       Impact factor: 3.857

10.  Morphine-like peptides in mammalian brain: isolation, structure elucidation, and interactions with the opiate receptor.

Authors:  R Simantov; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1976-07       Impact factor: 11.205

View more
  13 in total

1.  Hydrolysis of substance P in the presence of the osteosarcoma cell line SaOS-2: release of free amino acids.

Authors:  Antonella Cavazza; Mario Marini; L Giorgio Roda; Umberto Tarantino; Angela Valenti
Journal:  Neurochem Res       Date:  2011-08-21       Impact factor: 3.996

2.  Effects of combined neutral endopeptidase 24-11 and angiotensin-converting enzyme inhibition on femoral vascular conductance in streptozotocin-induced diabetic rats.

Authors:  V Arbin; N Claperon; M C Fournié-Zaluski; B P Roques; J Peyroux
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

Review 3.  Antigen presentation and the ubiquitin-proteasome system in host-pathogen interactions.

Authors:  Joana Loureiro; Hidde L Ploegh
Journal:  Adv Immunol       Date:  2006       Impact factor: 3.543

4.  Acute effect of the dual angiotensin-converting enzyme and neutral endopeptidase 24-11 inhibitor mixanpril on insulin sensitivity in obese Zucker rat.

Authors:  V Arbin; N Claperon; M C Fournié-Zaluski; B P Roques; J Peyroux
Journal:  Br J Pharmacol       Date:  2001-06       Impact factor: 8.739

5.  Effect of endopeptidase-24.11 inhibitors and C-ANP receptor ligand on responses evoked in arterioles of rat cremaster muscle by atrial natriuretic peptide.

Authors:  J Peyroux; F Beslot; N Claperon; M C Fournie-Zaluski; B P Roques
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

6.  Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: a potential therapeutic approach in hypertension.

Authors:  M C Fournié-Zaluski; W Gonzalez; S Turcaud; I Pham; B P Roques; J B Michel
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

7.  Development of [125I]RB104, a potent inhibitor of neutral endopeptidase 24.11, and its use in detecting nanogram quantities of the enzyme by "inhibitor gel electrophoresis".

Authors:  M C Fournié-Zaluski; J M Soleilhac; S Turcaud; R Laï-Kuen; P Crine; A Beaumont; B P Roques
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-15       Impact factor: 11.205

8.  The metabolism of neuropeptides. The hydrolysis of peptides, including enkephalins, tachykinins and their analogues, by endopeptidase-24.11.

Authors:  R Matsas; A J Kenny; A J Turner
Journal:  Biochem J       Date:  1984-10-15       Impact factor: 3.857

9.  A unique geometry of the active site of angiotensin-converting enzyme consistent with structure-activity studies.

Authors:  D Mayer; C B Naylor; I Motoc; G R Marshall
Journal:  J Comput Aided Mol Des       Date:  1987-04       Impact factor: 3.686

10.  High levels of functional endopeptidase 24.11 (CD10) activity on human thymocytes: preferential expression on immature subsets.

Authors:  B Mari; J P Breittmayer; S Guerin; N Belhacene; J F Peyron; M Deckert; B Rossi; P Auberger
Journal:  Immunology       Date:  1994-07       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.